EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Coronavirus Disease 2019 Vaccination Booster Effectiveness Based on the 2022 Japanese Dialysis Registry

Yuka Sugawara iD, Masao Iwagami, Yuki Sakurai, Kan Kikuchi, Masaomi Nangaku

Nephrology · 2025

DOI: 10.1111/nep.70093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology, 2025. Verfasst von Yuka Sugawara und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Immunization, Secondary, Renal Dialysis. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health, Labour and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate the effectiveness of the third, fourth, and fifth booster doses (rolled out in December 2021, June 2022, and October 2022, respectively) of the coronavirus disease 2019 (COVID‐19) vaccine in Japanese haemodialysis patients during the Omicron era.

Methods

We analysed the Japanese Society for Dialysis Therapy Renal Data Registry (JRDR) year‐end survey data from 2021 to 2022, which included information on the number of vaccinations and the most recent vaccination and infection months. For each month of 2022, the COVID‐19 infection and related mortality risks were calculated by vaccination status, followed by logistic regression analyses to estimate adjusted odds ratios (aORs).

Results

Overall, 225 887 patients were analysed, including 13 440 (5.9%), 25 547 (11.3%), 64 242 (28.4%), and 122 658 (54.3%) with ≤ 2, 3, 4, and 5 doses at the end of 2022, respectively. The third dose was significantly correlated with a lower risk of COVID‐19 infection in early 2022 (March: aOR 0.53 [0.43–0.64]; April: 0.77 [0.63–0.95]) but was associated with a higher risk during mid‐2022, coinciding with the BA.1/2 to BA.5 transition (July: 1.65 [1.39–1.95]; August: 2.37 [2.06–2.71]). The third dose consistently correlated with reduced COVID‐19‐related mortality. The fourth and fifth doses correlated with lower infection risk and COVID‐19‐related mortality throughout the period.

Conclusion

Among Japanese haemodialysis patients, the third to fifth COVID‐19 vaccine doses were associated with reduced infection risk (except in July and August for third doses) and mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesImmunization, SecondaryRenal DialysisVaccine EfficacyAgedFemaleHumansMaleMiddle AgedJapanRegistriesVaccinationEast Asian People

Stichwörter der Autor:innen

COVID‐19SARS‐CoV‐2coronavirushaemodialysiskidneyrenal insufficiencyvaccination

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Division of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan.
  • Department of Health Services Research, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
  • Division of Nephrology, Shimoochiai Clinic, Tokyo, Japan.

ORCID-Profile: Yuka Sugawara

Förderung

  • Ministry of Health, Labour and Welfare

Zitieren

APA

Sugawara, Y., Iwagami, M., Sakurai, Y., Kikuchi, K., & Nangaku, M. (2025). Coronavirus Disease 2019 Vaccination Booster Effectiveness Based on the 2022 Japanese Dialysis Registry. Nephrology. https://doi.org/10.1111/nep.70093

Vancouver

Sugawara Y, Iwagami M, Sakurai Y, Kikuchi K, Nangaku M. Coronavirus Disease 2019 Vaccination Booster Effectiveness Based on the 2022 Japanese Dialysis Registry. Nephrology. 2025. doi:10.1111/nep.70093

BibTeX
@article{Sugawara2025,
  author = {Sugawara, Yuka and Iwagami, Masao and Sakurai, Yuki and Kikuchi, Kan and Nangaku, Masaomi},
  title = {Coronavirus Disease 2019 Vaccination Booster Effectiveness Based on the 2022 Japanese Dialysis Registry},
  journal = {Nephrology},
  year = {2025},
  doi = {10.1111/nep.70093}
}
Kostenlos starten →